Nuvelo Reports Third Quarter 2008 Financial Results

... For the third quarter ended September 30, 2008, nuvelo reported a net loss of $8.5 million or $0.16 per s...007. For the nine months ended September 30, 2008, nuvelo reported a net loss of $27.2 million or $0.51 per ...rst nine months of 2008. As of September 30, 2008, nuvelo had $65.1 million in cash and cash equivalents, ma...

Nuvelo to Present at Jefferies 2nd Annual Healthcare Conference

...nd Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities. Information about nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000. ...

Nuvelo Announces Publication of Preclinical Data From Wnt Therapeutics Program

...oteins are novel regulators of the Wnt pathway and were first identified by nuvelo as potent gastrointestinal mitogens in transgenic mice (1). About Nuvelo ...eate additional partnering and licensing opportunities. Information about nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-51...

Nuvelo Announces Presentations on NU206 and rNAPc2 at 2008 American Association for Cancer Research Annual Meeting

...nd Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities. Information about nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000. This press release contains "forward-looking statements," which i...

Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation

...tion therapy-induced mucositis and inflammatory bowel disease. In addition, nuvelo expects to continue its research programs in leukemia and lymphoma therapeu...eate additional partnering and licensing opportunities. Information about nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-51...

Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation

...or Relations portion of Nuvelo's website at http://www.nuvelo.com . About nuvelo Nuvelo, Inc. is dedicated to improving the lives of patients through the d...reate additional partnering and licensing opportunities. Information about nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-51...

Nuvelo in Medical Technology

Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172

...has the potential for non-renal clearance. About nuvelo and Archemix's Joint Collaborative Effort In August 2006, nuvelo expanded its collaboration with Archemix to develo...acting aptamers for use in medical procedures, and nuvelo leads development and worldwide commercialization ...

Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172

...action, and avoidance of thrombocytopenia. About nuvelo and Archemix's Joint Collaborative Effort In August 2006, nuvelo expanded its collaboration with Archemix to develo...acting aptamers for use in medical procedures, and nuvelo leads development and worldwide commercialization ...

Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172

...action, and avoidance of thrombocytopenia. About nuvelo and Archemix's Joint Collaborative Effort In August 2006, nuvelo expanded its collaboration with Archemix to develo...acting aptamers for use in medical procedures, and nuvelo leads development and worldwide commercialization ...

Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models

...oteins are novel regulators of the Wnt pathway and were first identified by nuvelo as potent gastrointestinal mitogens in transgenic mice(1). About Nuvelo ...eate additional partnering and licensing opportunities. Information about nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-51...

Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development

...t the desired target product profile. As a result, nuvelo has ended further clinical development of alfimepr...n to discontinue alfimeprase clinical development, nuvelo will restructure to make additional resources avai...ontinued Dr. Love. Conference Call Information nuvelo will hold a conference call today at 4:30 p.m. Eas...

Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172

...ty to target protein-protein interactions. About nuvelo and Archemix's Joint Collaborative Effort In August 2006, nuvelo expanded its collaboration with Archemix to develo...acting aptamers for use in medical procedures, and nuvelo leads development and worldwide commercialization ...

Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke

...rase for the treatment of acute ischemic stroke. nuvelo has also been granted fast track designation by th...uring medical or surgical procedures. In addition, nuvelo expects to continue its research programs in leuke...g and licensing opportunities. Information about nuvelo is available at our website at http://www.nuvelo....

Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call

...t- acting anticoagulant during medical or surgical procedures. In addition, nuvelo expects to continue its research programs in leukemia therapeutic antibodie...create additional partnering and licensing opportunities. Information about nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-51...

Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion

...es for acute peripheral arterial occlusion. About nuvelo Nuvelo, Inc. is dedicated to improving the lives ...ng and licensing opportunities. Information about nuvelo is available at our website at http://www.nuvelo....ors are identified and described in more detail in nuvelo filings with the SEC, including without limitation...

Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session

...rt-acting anticoagulant during medical procedures. nuvelo is also advancing an emerging oncology pipeline, i...sitis and inflammatory bowel disease. In addition, nuvelo expects to leverage its expertise in secreted prot...g and licensing opportunities. Information about nuvelo is available at our website at

More>>

Nuvelo in Biological Technology

ARCA biopharma to Present at 27th Annual JPMorgan Healthcare Conference

... visit http://www.arcabiopharma.com . About nuvelo Nuvelo, Inc. is dedicated to improving the live...sitis and inflammatory bowel disease. In addition, nuvelo is pursuing research programs in leukemia and lymp...nd licensing opportunities. Information about nuvelo is available at its website at http://www.nuvelo....

Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma

... NUVO ) today announced that the stockholders of nuvelo have approved the issuance of nuvelo Common Stock pursuant to the merger agreement date... A substantial majority of the proxies received by nuvelo to date reflect votes cast in favor of both the pr...

Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc.

... If recent empirical evidence with respect to numerous other failed biotech companies is any guide (e.g., Corgentech, Renovis, Novacea, Nitromed, nuvelo and others), the future does not bode well for Avigen shareholders if left to its own devices. In one similar situation, the company could have retu...

Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers

...an and chief executive officer of Nuvelo. "Because nuvelo is in the process of merging with ARCA biopharma t...ory bowel disease, and bone disease. About nuvelo and Kyowa Hakko Kirin's Joint Collaborative Effort Scientists from nuvelo and Kyowa Hakko Kirin worked together to identify ...

Nuvelo and ARCA biopharma Advance Toward Completion of Merger

...A will become a wholly owned subsidiary of Nuvelo. nuvelo will issue new shares of its common stock to ARCA ...combined company on a fully-diluted basis. Current nuvelo stockholders are expected to own approximately 33 ... board, and three representatives from the current nuvelo board. The chief executive officer of the combined...

ARCA biopharma to Present at JMP Securities Healthcare Focus Conference

...sitis and inflammatory bowel disease. In addition, nuvelo is pursuing research programs in leukemia and lymp...g and licensing opportunities. Information about nuvelo is available at our website at http://www.nuvelo....factors, including, without limitation, failure of nuvelo or ARCA's stockholders to approve the merger, the ...

Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company

...y owned subsidiary of Nuvelo. Under the agreement, nuvelo will issue new shares of its common stock to ARCA ...ed basis, using the treasury stock method. Current nuvelo stockholders are expected to own approximately 33 ...ry stock method. The boards of directors of both nuvelo and ARCA have approved the definitive merger agree...

Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers

...l disease, bone disease and wound healing. About nuvelo and Kirin's Joint Collaborative Effort Scientists from nuvelo and Kirin worked together to identify and characte...used on the discovery of novel, secreted proteins. nuvelo signed a collaboration agreement with Kirin in Apr...

Nuvelo Reports Second Quarter 2008 Financial Results

...nts. For the second quarter ended June 30, 2008, nuvelo reported a net loss of $0.2 million or $0.00 per s...d in 2007. For the six months ended June 30, 2008, nuvelo reported a net loss of $18.6 million or $0.35 per ...the first six months of 2008. As of June 30, 2008, nuvelo had $76.0 million in cash and cash equivalents, ma...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...UTICS INC. (NASDAQ: CVTX ) EDWARDS LIFESCIENCES CORP (NYSE: EW ) MEDICINES COMPANY (NASDAQ: MDCO ) MOMENTA PHARMACEUTICALS INC (NASDAQ: MNTA ) nuvelo INC (NASDAQ: NUVO ) PAR PHARMACEUTICAL COS INC. (NYSE: PRX ) SANGAMO BIOSCIENCES INC. (NASDAQ: SGMO ) SCIELE PHARMA INC. (NASDAQ: SCRX ) SPEED...